Marotta et al. demonstrated that IL-6/JAK2/STAT3 signaling was particularly upregulated in CD44+CD24− BCSCs relative to other tumor cells and that JAK2 inhibition significantly reduced this population as well as tumorigenicity [136]. Here, JAK2 is linked to neoplasm.